Regulatory decisions, safety alerts, NHS access changes and trial
results, dated and sourced. Newest first. No opinion pieces, no product launches presented
as news, and negative trial results recorded the same as positive ones.
Over two days, the FDA's Pharmacy Compounding Advisory Committee voted to recommend that US compounding pharmacies be allowed to prepare BPC-157, KPV, TB-500 and MOTS-c, then on the second day added Epitalon and Semax. Emideltide was the only compound rejected. The votes were narrow, 8 to 6 with one abstention for the first three, and 7 to 5 with two abstentions for MOTS-c. FDA's own career scientists had reviewed all seven and recommended against every one, citing immunogenicity, peptide-related impurities and limited safety information. Agency staff also raised a more basic obstacle: without universally accepted chemical definitions for these substances, identity and quality cannot be reliably assessed in the first place.
What this means: Nothing changes in the UK. This is a US committee making a US recommendation, and it has no bearing on the MHRA. BPC-157 and TB-500 remain unlicensed medicines here, and supplying them for…
A NICE committee was due to meet in July 2026 to consider orforglipron, the once-daily oral non-peptide GLP-1, for NHS use in England and Wales. The appraisal follows the drug's US approval on 1 April 2026 and runs in parallel with the MHRA's own licensing decision, which has not yet been made. Published phase 3 figures from ATTAIN-1 reported weight reduction of 7.5 per cent, 8.4 per cent and 11.2 per cent across three dose levels over 72 weeks, against 2.1 per cent on placebo, in a trial funded by Eli Lilly.
What this means: A NICE appraisal starting is not the same as a drug becoming available, and the sequence trips people up constantly. Two separate things have to happen. The MHRA decides whether the drug…
Reporting on the MHRA's Yellow Card data records 1,176 reports of acute and chronic pancreatitis following tirzepatide use between January 2023 and June 2026, 18 of which had a fatal outcome. For liraglutide, 137 reports were made between 2020 and 2026, one with a fatal outcome. The figures follow the MHRA's drug safety alert of 29 January 2026 which highlighted acute pancreatitis as a known but infrequent side effect that can be fatal.
What this means: These numbers need holding at both ends, because they get misused in both directions. Yellow Card reports are suspicions, not confirmed cases. A report means someone thought there might be…
Trial results reported in July compared an oral GLP-1 against oral semaglutide directly, with the newer agent producing greater weight reduction. Like oral semaglutide, it requires no refrigeration, which coverage highlighted as an advantage for expanding access in countries where reliable cold chain storage is not available.
What this means: Head-to-head trials are worth far more than comparing separate studies, so this is a genuinely useful result rather than another press release. The refrigeration point is the part most…
A tablet form of semaglutide, branded Wegovy, went on sale in the UK on 6 July, the first GLP-1 medicine available as a pill rather than an injection. The MHRA approved it a month earlier. A National Pharmacy Association survey published on launch day reported that around three-quarters of pharmacies expected to start significant numbers of eligible patients on it.
A National Pharmacy Association survey of 310 UK pharmacy owners, published on the day oral Wegovy went on sale, found around three-quarters expected to start significant numbers of eligible patients on it, and 49 per cent had already seen more patient queries since the June approval. Ninety-seven per cent said they were concerned the new tablet would drive an increase in fake or unlicensed weight-loss pills sold on the black market.
What this means: A tablet is far easier to counterfeit convincingly than an injection pen, and far easier to post. That is the whole reason 97 per cent of pharmacists are worried. The practical rule has not…
Following the January safety alert on acute pancreatitis, the MHRA and UK Biobank are working together to establish whether there is a genetic link between GLP-1 medicines and drug-induced acute pancreatitis, similar to the known link with the immunosuppressant thiopurine. Reporting alongside this noted 137 Yellow Card reports of acute and chronic pancreatitis for liraglutide between 2020 and 2026, one of which had a fatal outcome.
What this means: This is how a rare side effect gets properly understood rather than just counted. If a genetic marker turns up, it could eventually mean a test that identifies the small number of people…
Two manufacturers have filed abbreviated new drug applications for generic tirzepatide. Acceptance of a filing is not approval, and the originator holds patents running to 2036, so this does not mean cheaper tirzepatide is imminent in the UK or anywhere else.
On 3 July the MHRA approved semaglutide injection for the treatment of a form of liver disease, the first time the drug has been licensed in the UK for an indication outside weight management, type 2 diabetes and cardiovascular risk reduction.
What this means: This is a genuinely new use rather than a relabelling, and it matters beyond the people it directly affects. Fatty liver disease is common, often silent, and has had almost no licensed drug…
The Medicare GLP-1 Bridge Program launched on 1 July 2026, giving eligible Medicare Part D enrollees access to specified GLP-1 products for obesity at a capped out-of-pocket cost of around 50 dollars a month. Under existing federal law Part D plans cannot cover medicines prescribed for weight loss, so the programme runs as a separate demonstration with a central Medicare system handling approvals and payments. It runs to 31 December 2027, after the Part D portion of a broader model was delayed indefinitely in May 2026.
What this means: Nothing here changes UK access. It is worth watching for a different reason: it is the largest test yet of what happens when a national payer opens the taps on these drugs. The UK is…
SYNCHRONIZE-CVOT, a phase 3 cardiovascular safety trial of survodutide involving 5,531 participants with overweight or obesity plus established cardiovascular disease, chronic kidney disease or multiple risk factors, reached its completion date at the end of March 2026. Two further phase 3 trials, LIVERAGE and LIVERAGE-Cirrhosis, are recruiting in the liver condition MASH, including in people with established cirrhosis.
What this means: Survodutide gets a fraction of the attention retatrutide does and is at a comparable stage of development. If you are trying to anticipate what reaches UK pharmacies over the next few…
Results from the ACCESS phase 2b trial of aleniglipron, an oral small-molecule GLP-1, were published in Nature Medicine. In 230 adults with obesity or overweight, placebo-adjusted weight reduction at 36 weeks was 8.2, 9.8 and 11.3 per cent across three dose levels. The authors reported no apparent plateau in weight loss by the end of the double-blind period, with further reduction seen at an interim analysis of the open-label extension.
What this means: Phase 2 means this is a promising early signal, not a finished drug. It is years from a UK pharmacy, if it gets there at all, and plenty of phase 2 successes fail in phase 3. The reason it…
An analysis using genetic evidence reported that GLP-1 receptor agonists achieve weight loss primarily by reducing fat mass rather than lean mass. Separately, a large real-world study reported that semaglutide was associated with a lower risk of bone fractures in people with type 2 diabetes.
What this means: This goes directly against one of the most widely repeated claims about these drugs: that they strip muscle along with fat and leave you weaker. That claim was never baseless. Any…
Results from SOLSTICE, a multicentre phase 2b randomised placebo-controlled trial of elecoglipron, an oral small-molecule GLP-1 receptor agonist, were published in The Lancet and presented at the American Diabetes Association's Scientific Sessions. The trial was in adults with type 2 diabetes and reported effects on both blood glucose control and body weight.
What this means: The individual result matters less than the count. This is the fourth oral small-molecule GLP-1 to report solid mid-stage or late-stage data, after orforglipron's US approval, aleniglipron…
Results from the STEP UP trial reported greater average weight loss at a higher semaglutide dose than the currently licensed maximum. A trial result is not a licence: any change to approved dosing requires a regulatory submission and assessment first.
The MHRA licensed oral semaglutide, branded Wegovy, for weight management on 11 June. It is licensed for adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related health condition. Treatment starts at the lowest strength and steps up at intervals of at least a month. The tablet must be swallowed whole on an empty stomach with a sip of water after fasting for at least eight hours. The MHRA said patients already on the weekly injection privately can move straight across to the highest tablet strength.
What this means: The headline is that you no longer need a needle. The detail is that you do need an empty stomach and an eight-hour fast, every single day, which is a real constraint the coverage tends to…
The SOUL trial reported a reduction in major adverse cardiovascular events among adults with type 2 diabetes at high cardiovascular risk. Cardiovascular outcome trials matter more than weight figures for judging long-term benefit, and they take years to run.
The American College of Physicians published a living clinical guideline establishing semaglutide and tirzepatide as conditional first-line pharmacological options for obesity. The guideline sits alongside separate specialty frameworks published the same month setting out how obesity care should be integrated across services.
What this means: This is American guidance and does not bind anyone in the UK, where NICE decides. It still matters, for one reason: it marks the point where these drugs stopped being treated as a last…
The EVOKE and EVOKE+ trials, enrolling over 3,800 people across two years, found no difference in Alzheimer's disease progression. This is worth recording precisely because it is a negative result. GLP-1 drugs have been widely speculated about for conditions well beyond diabetes and weight, and most of those hypotheses will fail.
An investigative report published in June, alongside reported MHRA enforcement activity in the UK and a sharp rise in poison centre contacts in the United States, brought fresh attention to unlicensed retatrutide sold online. Retatrutide has no marketing authorisation in any country and cannot be lawfully supplied for human use.
A systematic review and meta-analysis of 16 randomised trials covering 23,467 participants with obesity but not diabetes, over a median 68 weeks, reported a 20 per cent reduction in major adverse cardiovascular events. Effects were strongest for stroke, then heart attack, then hospitalisation for heart failure, alongside reductions in blood pressure, triglycerides and inflammatory markers. Mediation analysis suggested that between 35 and 55 per cent of the cardiovascular benefit was independent of weight loss itself.
What this means: A meta-analysis pools many trials, so it carries more weight than any single one. This is among the stronger pieces of evidence in the whole field. The genuinely interesting finding is the…
Researchers identified genetic variants associated with reduced response to GLP-1 receptor agonists used in type 2 diabetes, reporting that roughly 10 per cent of the population carries them.
What this means: This is the beginning of an answer to a question a lot of people have been asking: why do these drugs work spectacularly for some people and barely at all for others? If it holds up, it…
The FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the list of bulk substances that outsourcing facilities may compound, on the basis that there is no clinical need. This is a US matter with no direct UK effect, but compounded product from US sources has been a route into the UK grey market.
The MHRA began investigating UK clinics making therapeutic claims about unregulated peptide products. BPC-157 was reported as the first compound named. The regulator's stated position is that the products are unlicensed and the marketing has run ahead of the evidence.
In April, the FDA removed BPC-157, TB-500 and CJC-1295 from Category 2 of its bulk substances list, the category indicating agency safety concerns, after the nominations for those substances were withdrawn. It did not move them to Category 1, the list of substances permitted for compounding, and none has an approved drug containing it or a recognised pharmacopoeia monograph.
What this means: This is the story that made July's advisory committee vote possible, and it was widely misreported at the time as the FDA softening its position. Coming off a safety-concern list is not the…
Guidance covering implementation of NICE TA1026 for tirzepatide in obesity was published, setting out the requirement for wrap-around care alongside prescribing. NICE guidance effectively mandates that support, so tirzepatide is not funded as a standalone treatment.
From 1 April, prescribing of tirzepatide for obesity was incorporated into the 2026/27 GP contract through new Quality and Outcomes Framework indicators. Participation by practices is optional, so meeting the eligibility criteria does not guarantee access, and availability varies by area.
On 5 February the MHRA updated product information for prescribers and patients regarding the risk of non-arteritic anterior ischaemic optic neuropathy, or NAION, in people taking semaglutide. NAION involves reduced blood flow to the front of the optic nerve and typically causes sudden, painless loss of vision in one eye. The MHRA said studies suggest the association is very rare, meaning it may affect up to 1 in 10,000 people taking the drug.
What this means: Very rare means very rare. Up to 1 in 10,000 is the regulator's own framing, and for almost everyone this will not change the decision to take it or not. What it does change is what you…
The MHRA issued an alert about falsified 15 mg Mounjaro KwikPens in circulation. Product bought anywhere other than a registered pharmacy cannot be verified as containing what the label states.
The MHRA issued a drug safety alert and updated product information for GLP-1 medicines to highlight acute pancreatitis as a known but infrequent side effect that can be fatal. Patients were advised to be alert to severe, persistent stomach pain that may spread to the back, with nausea or vomiting. Anyone experiencing that should seek medical attention rather than wait.
In October 2025 the MHRA seized over 2,000 unlicensed weight-loss injection pens along with raw chemical ingredients, in what it described as believed to be the largest single seizure of trafficked weight-loss medicines ever recorded by a law enforcement agency anywhere. A separate investigation published in November 2025 found videos on TikTok promoting retatrutide, which is not approved in any country.
What this means: Two thousand pens is not a hobbyist operation. The raw ingredients alongside them are the detail that matters: someone was manufacturing, not just reselling. That is the honest answer to…
Included: MHRA licensing decisions and safety alerts, NICE appraisals and
criteria changes, NHS access and commissioning changes, published trial results
including negative ones, enforcement action, and counterfeit warnings.
Excluded: price changes and promotions, clinic and pharmacy announcements,
anything sourced only to a company press release, and preliminary figures released
by announcement rather than publication. Where an item is still awaiting a check
against its primary source, it says so on the item.